https://www.taxtmi.com/news?id=51236 Phase III clinical trial enrollment for the indigenous single dose dengue vaccine 'DengiAll' has exceeded seventy percent in a multicentre, randomised, double blind, placebo controlled study evaluating efficacy, immunogenicity and safety across sites selected to represent circulation of all four dengue virus serotypes; the trial involves over ten thousand participants at twenty sites and operates alongside central monitoring, designated surveillance laboratories, national management guidelines, and state support for preparedness and vector control. en-us Fri, 01 Aug 2025 15:01:03 +0530 Fri, 01 Aug 2025 15:01:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=51236 Phase III clinical trial enrollment for the indigenous single dose dengue vaccine 'DengiAll' has exceeded seventy percent in a multicentre, randomised, double blind, placebo controlled study evaluating efficacy, immunogenicity and safety across sites selected to represent circulation of all four dengue virus serotypes; the trial involves over ten thousand participants at twenty sites and operates alongside central monitoring, designated surveillance laboratories, national management guidelines, and state support for preparedness and vector control. News - Fri, 01 Aug 2025 15:01:03 +0530 https://www.taxtmi.com/news?id=51236